Charles River Acquires Cerebricon LTD
August 4, 2009 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Cerebricon Ltd. Cerebricon, located in Kuopio, Finland, brings together MRI (magnetic resonance imaging) techniques, biomarkers and behavioral measurements in gold standard assays for acute neurology (such as stroke and spinal cord injury), chronic neurology (including multiple sclerosis and Alzheimer’s and Parkinson’s disease) and psychiatry (exemplified by ADHD, schizophrenia and depression).
Through our Discovery and Imaging Services group, which includes MIR Preclinical Services (acquired in 2008) and Piedmont Research Center (acquired in 2009), we have established ourselves as a premier provider of non-GLP pharmacology and in vivo imaging services for the evaluation of compound efficacy. Our therapeutic areas of expertise now span oncology, cardiovascular, metabolism, inflammation and CNS, all of which are areas of increasing R&D focus.
For more information, please call 1.877.CRIVER.1 (1.877.274.8371) or email us at askcharlesriver@crl.com.